Bioabsorbable Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.
You may also be interested in...
ACC Wrap-Up: Device Companies Win a Few, Lose a Few
Several interesting studies came out of this year's joint meeting of the American College of Cardiology and Society for Cardiovascular Angiography and Interventions. These studies--many of them about drug-eluting stents--will impact device manufacturers in both positive and negative ways.
Stent Recap: Turmoil in 2007--What's Ahead for Interventional Cardiology?
Although safety concerns about drug-eluting stents have been mitigated somewhat by recent reports of more positive clinical data, there is lingering unease and confusion in the cardiology community about when, how, and in whom to use these devices. There is also a growing wave of healthy skepticism about the way stent trials are designed and conducted, and whether evidence- based medicine is well served by the current process.
Arterial Remodeling Technologies
Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.